Compare Amphastar Pharmaceuticals Inc (AMPH) vs AST SpaceMobile Inc (ASTS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs AST SpaceMobile Inc — how do they compare? Amphastar Pharmaceuticals Inc trades at $18.72 (market cap $826.08M), while AST SpaceMobile Inc trades at $71.89 (market cap $21.90B). The key difference: AST SpaceMobile Inc is far larger — about 26.5× Amphastar Pharmaceuticals Inc's market cap, and AST SpaceMobile Inc is trading nearer its 52-week high, Amphastar Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| AMPH | ASTS | |
|---|---|---|
Market Cap | $826.08M | $21.90B |
Sector | Health | Media |
52-Week High | $30.81 | $133.09 |
52-Week Low | $16.87 | $36.91 |
Enterprise Value | $1.22B | $21.87B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
ASTS trades at $73.32, down 0.76% on the day, with a bearish technical signal from moving averages and mixed oscillators. The company reported revenue of $70.92 million in 2025 but sustained a net loss of $341.94 million, missing earnings expectations for three consecutive quarters. Recent news highlights potential in defense communications via satellite technology, though competition with SpaceX remains a focal point.
The outlook is speculative with high execution risk; analyst consensus is divided with a $90.33 price target. Investment opportunity hinges on successful satellite deployment and partnership execution, but persistent losses and intense competition pose significant downside risks for shareholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About AST SpaceMobile Inc
AST SpaceMobile Inc is a satellite designer and manufacturer. The company is building the global cellular broadband network in space to operate directly with standard, unmodified mobile devices based on extensive IP and patent portfolio. AST is on a mission to eliminate the connectivity gaps faced by mobile subscribers and finally bring broadband to the billions who remain unconnected.
Read more on ASTS →
